Song J H, He X, Lou W S, Chen L, Chen G P, Su H B, Shi W Y, Wang T, Zhao B X, Gu J P
Department of Interventional Radiology, Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China.
Zhonghua Yi Xue Za Zhi. 2017 Apr 4;97(13):991-995. doi: 10.3760/cma.j.issn.0376-2491.2017.13.006.
To evaluate the clinical value of percutaneous AngioJet thrombectomy in treatment of acute symptomatic portal and superior mesenteric venous thrombosis venous thrombosis (PVMVT) . From January 2014 to January 2016, a total of 8 patients in Nanjing First Hospital with PVMVT verified by color Doppler ultrasound and computed tomographic angiography (CTA) were analyzed retrospectively. Under ultrasound guidance , the branch of the right portal vein(PV) was punctured with a micropuncture set and a 4-F infusion catheter was advanced to the superior mesenteric vein(SMV). The venogram demonstrated the thrombosis in the PV/SMV and a 6-F AngioJet Xpeeedior catheter was advanced over the guidewire and positioned in the distal SMV. Percutaneous thrombectomy was performed after a mixture of 250 000 U of urokinase in 100 ml of normal saline for mechanical pulse spray of thrombus in all patients for approximately 15 minutes. 2 patients underwent PTA and stent implantation after the thrombectomy procedure, 1 of them and the others 6 patients received continuous transcatheter infusion of urokinase (500 000 U/d) for 24 or 48 hours until the thrombosis was completely dissolved confirmed by angiography at 24 and 48 hours.After procedure and the thrombolytic therapy was discontinued, removal of the infusion catheter and the sheath from the liver, the transhepatic tract was embolized with coils or gelfoam to reduce the risk of bleeding. The patency rate of PV /SMV was assessed by CTA at 1 and 6 months after the procedure. Patients were discharged with oral anticoagulation regimen for at least 6 months.The following criteria were used in evaluation of thrombolysis: grade Ⅰ<50% thrombus removal; grade Ⅱ 50%90% thrombus removal, and grade Ⅲ>90% thrombus removal. All 8 patients with PVMVT were treated by AngioJet thrombectomy. Angiography after the thrombectomy procedure showed complete thrombus removal (>90%) was in 3 cases, substantial thrombus removal (50%90%) in 5 cases. Grade Ⅲ (complete) thrombolysis was achieved in 7 cases and grade Ⅱ (50%~90%) lysis in 1 case post thrombolytic therapy for 24 or 48 hours. 2 patients had underwent PTA and stent implantation. Large volume intraperitoneal hemorrhage was discovered in 1 patient after removal of the catheter and sheath from the liver. The patient restored stability after a blood transfusion.Venous patency was comfirmed in all 8 patients at 1 or 6 months after the treatment. There was no patient with major complications death related to the procedure. Percutaneous AngioJet thrombectomy with adjunctive thrombolytic therapy is an effective and safe treatment modality in patients with acute symptomatic PVMVT.
评估经皮AngioJet血栓切除术治疗急性症状性门静脉和肠系膜上静脉血栓形成(PVMVT)的临床价值。回顾性分析2014年1月至2016年1月南京第一医院8例经彩色多普勒超声和计算机断层血管造影(CTA)证实为PVMVT的患者。在超声引导下,用微穿刺套件穿刺右门静脉分支,将4F输注导管推进至肠系膜上静脉(SMV)。静脉造影显示门静脉/肠系膜上静脉血栓形成,将6F AngioJet Xpeeedior导管沿导丝推进并置于肠系膜上静脉远端。所有患者均在100ml生理盐水中加入25万U尿激酶混合后进行经皮血栓切除术,机械脉冲喷射血栓约15分钟。2例患者在血栓切除术后接受了经皮腔内血管成形术(PTA)和支架植入,其中1例以及其他6例患者接受了24或48小时的持续经导管尿激酶输注(50万U/d),直到24小时和48小时血管造影证实血栓完全溶解。术后及溶栓治疗停止后,从肝脏取出输注导管和鞘管,用弹簧圈或明胶海绵栓塞经肝通道以降低出血风险。术后1个月和6个月通过CTA评估门静脉/肠系膜上静脉的通畅率。患者出院时接受至少6个月的口服抗凝治疗。溶栓评估采用以下标准:Ⅰ级<50%血栓清除;Ⅱ级50%90%血栓清除,Ⅲ级>90%血栓清除。所有8例PVMVT患者均接受了AngioJet血栓切除术。血栓切除术后血管造影显示3例血栓完全清除(>90%),5例血栓大量清除(50%90%)。溶栓治疗24或48小时后,7例达到Ⅲ级(完全)溶栓,1例达到Ⅱ级(50%~90%)溶栓。2例患者接受了PTA和支架植入。1例患者在从肝脏取出导管和鞘管后出现大量腹腔内出血。输血后患者恢复稳定。治疗后1个月或6个月所有8例患者静脉均通畅。无患者因该手术出现严重并发症死亡。经皮AngioJet血栓切除术联合溶栓治疗是急性症状性PVMVT患者一种有效且安全的治疗方式。